La Jolla Pharmaceutical — Investor Presentation (February 2013)
51 slides from La Jolla Pharmaceutical's investor presentation, Feb 4, 2013
Slide 1: Pioneering Innovative Therapies to Treat Chronic Organ Failure and Cancer
Pioneering Innovative Therapies to Treat Chronic Organ Failure and Cancer George F. Tidmarsh, MD, PhDChief Executive OfficerJanuary 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp
Slide 3: An Introduction to La Jolla
An Introduction to La Jolla (LJPC) The Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 3
Slide 4: Mission
Mission La Jolla Pharmaceutical: Reducing Human SufferingNovel Therapies Harnessing the Immune SystemTo Treat Life-Threatening Diseases 4
Slide 5: Corporate Highlights
Corporate Highlights 5 Technology Immune therapy platform targeting Galectin-3, an innate protein with a demonstrated role in organ failure and cancer via immune regulationClear path to proof-of-conceptPipelineProduct candidate: GCS-100 - Leading, clinical stage galectin-3 antagonistMay prevent or r
Slide 6: Robust Product Pipeline
~~ Robust Product Pipeline 665100 ChenckKieney 000 > Kidney Disease End Stage Renal Disease turc-so1 Ent Sie Rea ee * a> scsi SHC VP > Liver — Disease Lipc21 Hepat boss «= PD> Cancer » 610 ig TY > Lipc.301 Sold Tuo PR > , ou Cancer
Slide 7: The Technology of La Jolla
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 7
Slide 8: Galectins and Galectin-3
Galectins and Galectin-3 8 Galectins are proteins that can bind to specific sugars on other proteins (receptors) to modulate cellular function and communication. Galectin 3 is unique in that it can self-associate allowing it to bind to several receptors at once. Gal-3 is normally present at low conc
Slide 9: GCS-100: The Leading Galectin-3 Antagonist
GCS-100: The Leading Galectin-3 Antagonist GCS-100 is a well-characterized, complex sugar derived from pectinGCS-100 binds to and neutralizes galectin-3. Binding activity is localized to the galactose containing side-branchesPatented manufacturing process required for biologic activity; unmodified p
Slide 10: GCS-100 and Organ Failure
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 10
Slide 11: Galectin-3 and Organ Failure: Kidney, Heart, Liver
Galectin-3 and Organ Failure Kidney, Heart, Liver Mice lacking galectin-3 develop significantly less kidney fibrosis and failure after damage compared to normal mice1,2 Mice lacking galectin-3 develop significantly less liver fibrosis when exposed to toxin3Galectin-3 serum assay is FDA approved to i
Slide 12: Galectin-3 in the General Population
Galectin-3 in the General Population 12
Slide 13: Galectin-3 in the General Population
Galectin-3 in the General Population High galectin-3 is independently associated with lower survival in the general population 13 Journal of Internal Medicine, 2012, 272; 55-64.
Slide 14: Galectin-3: Promotes Organ Failure via Scar Formation
Galectin-3: Promotes Organ Failure via Scar Formation Mice genetically altered to lack galectin-3 produce much less scar tissue in the kidney after injury. Normal (wild-type, WT) mice or galectin-3 knockout mice were either left alone (-) or surgically injured by obstructing the outflow of urine fro
Slide 15: Chronic Kidney Disease Market
Chronic Kidney Disease Market 49 million Americans suffer with CKD1$7.1 billion spent on CKD therapeutics in 20102Market growth of 6.4% CAGR over the next 5 years2 15 The United States Renal Data System, 2012 Annual Data Report Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Mark
Slide 16: Liver Disease Market
Liver Disease Market 16 The National Institute of Diabetes and Digestive and Kidney Diseases Liver Disease Treatments: The Global Market, January 1, 2012 BCC Research 17.5 million Americans suffer with CLD1$12.4 billion spent on CLD therapeutics in 20102CLD market growth of 3.3% CAGR expected until
Slide 17: GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model
GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model 17 Boehringer Ingelhiem GmbH & Co. KGGalectin Therapeutics Effect of GCS-100 in liver fibrosis was studied by an independent, contract research groupThe 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD 20
Slide 18: Stelic NASH Model
Stelic NASH Model 18 Treatment Control GCS-100 1 mg/kg GCS-100 25 mg/kg Endpoints Pathology Serum Chemistry NAFLD Score Fibrosis
Slide 19: GCS-100 Treatment Reduced Liver Fibrosis
GCS-100 Treatment Reduced Liver Fibrosis 19 Each circle represents data from one mouse.
Slide 20: GCS-100 Treatment Reduced Liver Fibrosis
GCS-100 Treatment Reduced Liver Fibrosis 20
Slide 21: GCS-100 Treatment Reduced Disease Activity
GCS-100 Treatment Reduced Disease Activity 21
Slide 22: GCS-100 Improved Gross Pathology
GCS-100 Improved Gross Pathology 22 Vehicle GCS-100
Slide 23: GCS-100 Improved Microscopy Pathology
GCS-100 Improved Microscopy Pathology 23
Slide 24: GCS-100 Reduced Liver Damage: Liver Enzymes
GCS-100 Reduced Liver Damage: Liver Enzymes 24 Normal Value p < 0.05
Slide 25: GCS-100 Effect of NASH: Summary
GCS-100 Effect of NASH: Summary Significant reduction in fibrosis as measured by Sirius Red stainingSignificant reduction in NAFLD scoreSignificant reduction in plasma ALTNo change in:Body weightSerum glucoseLiver weightLiver hydroxyprolineCollagen mRNA 25
Slide 26: GCS-100 and Cancer
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 26
Slide 27: Galectin-3 and Cancer
Galectin-3 and Cancer Over-expression of galectin-3 correlates with aggressiveness and relapse in multiple human cancers1,2 Galectin-3 expression increases the spread of cancer in animal models1,2 Galectin-3 suppresses anti-tumor T-cell activity3Lung tumor formation is reduced in galectin-3 -/- vs.
Slide 28: Galectin-3 Expression Correlates with Reduced Patient Survival
Galectin-3 Expression Correlates with Reduced Patient Survival Survival curve of colorectal cancer patients with positive and negative galectin-3 expression. The prognosis of patients was significantly worse in patients with galectin-3-positive expression (purple line) than in galectin-3- negative p
Slide 29: Galectin-3 Suppresses T-Cell Activation
Galectin-3 Suppresses T-Cell Activation 29 Source: Pierre van der Bruggen, Ludwig Institute for Cancer Research Galectin-3 Galectin-3 binding to cell surface glycoproteins blocksco-receptor association and cell signal transmission
Slide 30: GCS-100 Reverses Galectin-3 T-Cell Suppression
GCS-100 Reverses Galectin-3 T-Cell Suppression 30 Source: Pierre van der Bruggen, Ludwig Institute for Cancer Research Galectin-3 GCS-100
Slide 31: GCS-100 Reverses Galectin-3 T-Cell Suppression
GCS-100 Reverses Galectin-3 T-Cell Suppression T-cells were collected from 4 ovarian cancer patients and tested for their ability to kill the tumor (T-cell Activity). Untreated cells have little activity. After treating the T-cells with either an antibody to galectin-3 (purple) or with GCS-100 (blue
Slide 32: GCS-100 Improves Melanoma Cancer Vaccine
GCS-100 Improves Melanoma Cancer Vaccine Animals treated with GCS-100 in addition to a vaccine against the tumor live much longer than untreated animals or animals treated with vaccination or GCS-100 alone 32 Source: Dermotte et al. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and
Slide 33: Cancer Immunotherapy Market
Cancer Immunotherapy Market $1.7 billion spent on cancer immunotherapy in 2010121% CAGR for cancer vaccine market from 2010 to 20171Current ProductsYervoyTM (BMS)ProvengeTM (Dendreon) 33 GBI Research, "Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III
Slide 34: GCS-100's History in the Clinic
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 34
Slide 35: GCS-100 Clinical Summary
GCS-100 Clinical Summary 150 patients dosed in 9 Phase 1 and Phase 2 clinical trialsSignificant clinical activity in multiple cancers, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), renal cell carcinomaPharmacokinetic parameters establishedSingle- and multiple-dose administrati
Slide 36: GCS-100 Side Effects Consistent with Immune Modulation
GCS-100 Side Effects Consistent with Immune Modulation Doses up to 160 mg/m2 well tolerated in 24-patient solid tumor study Minimal hematological toxicityOnly drug-related grade 3 AEs = rash (8%), arthralgia (8%) and myalgia (4%), all consistent with immune effectsDose-Limiting ToxicityGrade 3 rashR
Slide 37: Phase 2a Single-Agent CLL Study: Design
Phase 2a Single-Agent CLL Study: Design Enrolled 24 patients with one or two prior therapiesMedian age 67 years old; 15 patients > 67 years, 4 > 80 yearsPrior therapies include multi-drug chemotherapyDosing regimen160 mg/m2 i.v. daily for 5 days on 21-day cycleRegimen from Phase 1 solid tumor studyS
Slide 38: Phase 2a Single-Agent CLL Study: Results
Phase 2a Single-Agent CLL Study: Results GCS-100 was well tolerated Minimal hematologic toxicity1 patient discontinued due to rashNo drug-related SAEsIn vivo evidence of expected biologic effect16/24 patients (25%) achieved partial remission and 12/24 (50%) achieved stable disease, (75% disease cont
Slide 39: GCS-100 Clinical Summary
GCS-100 Clinical Summary Clinical activity in multiple cancer typesWell tolerated and has low toxicity based on >140 patients treatedBroad-based synergy in vitro with both chemotherapy and other targeted agentsSingle agent activity observedRash, arthralgias, myalgias and increase in neutrophil count
Slide 40: Phase 1/2 Clinical Trial
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 40
Slide 41: Next Steps: Clinical Trial Rationale
Next Steps: Clinical Trial Rational Galectin-3 is increased and the level correlates to overall survival in end-stage renal disease patientsGalectin-3 knockout mice develop less kidney scar after injuryPatients with chronic kidney disease have no existing therapeutic options outside of renal transpl
Slide 42: CKD Phase 1/2 Trial Part A
CKD Phase 1/2 Trial 42 Part A Day-21 Day-8 Day0 Day7 Screening Visit 1 Screening Visit 2 Each cohort n=3 patients(up to 6 cohorts) GCS-1001.5-20 mg/m2 IV D-0 D - -21,-8 Data collected on:Blood gal-3, Cytokine, Serum chemistry, Quantitative urine analysis, and eGFR rate Data Collection Point Dosing P
Slide 43: CKD Phase 1/2 Trial Part B
CKD Phase 1/2 Trial 43 Part B Day0 Day7 Day49 Day56 D - 0,7 n=18 patients GCS-1001.5-20 mg/m2 IV D-0 D-7 D-21 D-28 D-35 D-42 D-49 Data collected on:Blood gal-3, Cytokine, Serum chemistry, Quantitative urine analysis, and eGFR rate Data Collection Point Dosing Point Key Day14 D-14 Day28 Day42 Day35 D
Slide 44: Phase 1/2 Study in Chronic Kidney Disease
Phase 1/2 Study in Chronic Kidney Disease First Patient Dosed with GCS-100 4 leading sites in the USRapid enrollment anticipatedAccelerated path to Phase 2 DataSingle-dose, dose-escalation Phase 1 (Part A)Endpoints:Maximum tolerated doseSafety Multiple dose Phase 2 (Part B)Endpoints:Kidney functionS
Slide 45: Patents and Financials
An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 45
Slide 46: Intellectual Property Position
Title Status Expiration Modified Pectins, Compositions and Methods Related Thereto Issued US 8,128,966 2028 Modified Pectins, Compositions and Methods Related Thereto Issued US 8,187,642 2025 Modified Pectins, Compositions and Methods Related Thereto Pending US 13/588,932 2025 Modified Pectins, Comp
Slide 47: Key Financial Information
Key Financial Information As of Q3 2012 Cash was $3,363,000Will take us through 2013Additional $10,646,000 in secured financingWill take us through 20152013 projected R&D spending to be 60% of total cash burn319% increase in R&D spending from 2012 47
Slide 48: Stock Information
Stock Information Stock Information 48
Slide 49: Robust Product Pipeline
~~ Robust Product Pipeline 6c8-100 Chenickiney se > Kidney Disease End Stage Renal Disease turc-so1 Ent Sie Rea ee * a> scsi SHC VP > Liver — Disease Lipc21 Hepat boss «= PD> ecs-100 A TR) > Immunemodton Lupc.s0t a Cancer « ou
Slide 50: Corporate Highlights
Corporate Highlights Technology Immune therapy platform targeting, Galectin-3, an emerging key with a demonstrated role in organ failure and cancer via immune regulationClear path to proof-of-conceptStrong IP position with broad, issued patents PipelineProduct candidate: GCS-100 - Leading, clinical
Slide 51: Thank You
/ @La Jolla Pharmaceutical Thank You
LA Jolla Pharmaceutical — Investor Presentation (February 2013) on 6ix